Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) was upgraded by stock analysts at Wells Fargo & Company from a “hold” rating to a “strong-buy” rating in a report released on Tuesday, MarketBeat reports. The firm currently has a $509.00 target price on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 66.85% from the company’s previous close.
Several other analysts have also weighed in on PRAX. HC Wainwright reaffirmed a “buy” rating on shares of Praxis Precision Medicines in a report on Wednesday, November 11th. JPMorgan Chase & Co. initiated coverage on Praxis Precision Medicines in a report on Friday, October 16th. They issued an “overweight” rating and a $700.00 target price on the stock. Royal Bank Of Canada increased their price target on Praxis Precision Medicines from $462.00 to $478.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 10th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $575.00 price target (up from $470.00) on shares of Praxis Precision Medicines in a report on Friday, August 21st. Finally, BTIG Research reiterated a “buy” rating and issued a $826.00 price objective on shares of Praxis Precision Medicines in a research report on Monday, November 9th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $656.42.
Read Our Latest Stock Analysis on PRAX
Praxis Precision Medicines Stock Performance
PRAX opened at $305.06 on Tuesday. The firm has a market cap of $8.53 billion, a price-to-earnings ratio of -23.83 and a beta of 2.85. The firm’s 50-day simple moving average is $288.12 and its 200-day simple moving average is $314.34. Praxis Precision Medicines has a twelve month low of $160.11 and a twelve month high of $392.70.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($3.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.54) by $0.31. As a group, sell-side analysts anticipate that Praxis Precision Medicines will post -13.72 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the stock. Algert Global LLC lifted its holdings in Praxis Precision Medicines by 4.5% during the 3rd quarter. Algert Global LLC now owns 18,268 shares of the company’s stock worth $5,320,000 after buying an additional 790 shares in the last quarter. Allworth Financial LP boosted its position in Praxis Precision Medicines by 217.9% in the 3rd quarter. Allworth Financial LP now owns 248 shares of the company’s stock valued at $72,000 after buying an additional 170 shares during the last quarter. Aquatic Capital Management LLC bought a new position in Praxis Precision Medicines in the 3rd quarter valued at $2,148,000. Bellevue Group AG increased its stake in shares of Praxis Precision Medicines by 261.5% in the 3rd quarter. Bellevue Group AG now owns 6,676 shares of the company’s stock valued at $1,944,000 after buying an additional 4,829 shares during the period. Finally, Cetera Investment Advisers acquired a new stake in shares of Praxis Precision Medicines in the 3rd quarter valued at $284,000. Institutional investors own 67.84% of the company’s stock.
Praxis Precision Medicines Company Profile
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.
Featured Stories
- Five stocks we like better than Praxis Precision Medicines
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
